Jia Xinyu, Chen Yujie, Gao Yagang, Ren Xue, Du Bing, Zhao Hanqing, Feng Yanling, Xue Guanhua, Cui Jinghua, Gan Lin, Feng Junxia, Fan Zheng, Fu Tongtong, Xu Ziying, Yu Zihui, Yang Yang, Zhao Shuo, Huang Lijuan, Ke Yuehua, Liu Chuanhe, Yan Chao, Yuan Jing
Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China.
Department of Allergy, Children's Hospital of Capital Institute of Pediatrics, Beijing, China.
Front Cell Infect Microbiol. 2024 Dec 20;14:1478087. doi: 10.3389/fcimb.2024.1478087. eCollection 2024.
(), a common pathogen of community-acquired pneumonia in school-age children and adolescents, can cause epidemics worldwide. In late 2023, the incidence of infection among children reached a high level.
We investigated the antimicrobial susceptibility of 62 isolates obtained from children with pneumonia in Beijing between 2021 and 2023, and analyzed the correlation of antimicrobial susceptibility with molecular characteristics of isolates and clinical manifestations of patients.
The resistance rates of isolates against erythromycin and azithromycin were both 100% (62/62). The minimum inhibitory concentration (MIC) of acetylspiramycin (16-membered macrolides) was lower than that of erythromycin and azithromycin. The MIC of azithromycin in 2023 was notably higher compared to 2021 and 2022. No resistance to tetracycline and levofloxacin was observed. Genotypes P1 type 1 and P1 type 2 were identified in 74.2% and 25.8% of isolates, and M4-5-7-2 (61.3%) and M3-5-6-2 (22.6%) were predominant multi-locus variable-number tandem-repeat analysis (MLVA) types. The A2063G mutation was present in all isolates (100%). Among the patients, 45/59 cases (76.3%) had severe pneumonia, and 14/59 cases (23.7%) presented co-infection. The duration of fever was 12 days (1-30 days) and the fever duration after initiation of macrolide antibiotics treatment was 8 days (1-22 days).
Our study showed that macrolide-resistant (MRMP) with high antimicrobial resistance level may be the causative factor of the epidemic in late 2023 in Beijing, China. It is urgent to pay more attention to MRMP and the antibiotics choose.
(病原体名称未给出)是学龄儿童和青少年社区获得性肺炎的常见病原体,可在全球范围内引起流行。2023年末,儿童中该病原体感染发病率达到高水平。
我们调查了2021年至2023年期间从北京肺炎患儿中分离出的62株(病原体名称未给出)的抗菌药物敏感性,并分析了抗菌药物敏感性与分离株分子特征及患者临床表现之间的相关性。
分离株对红霉素和阿奇霉素的耐药率均为100%(62/62)。乙酰螺旋霉素(16元大环内酯类)的最低抑菌浓度低于红霉素和阿奇霉素。2023年阿奇霉素的最低抑菌浓度明显高于2021年和2022年。未观察到对四环素和左氧氟沙星的耐药情况。在74.2%和25.8%的分离株中分别鉴定出P1型1和P1型2基因型,多基因座可变数目串联重复分析(MLVA)类型中M4 - 5 - 7 - 2(61.3%)和M3 - 5 - 6 - 2(22.6%)为主。所有分离株(100%)均存在A2063G突变。在患者中,45/59例(76.3%)患有重症(病原体名称未给出)肺炎,14/59例(23.7%)出现合并感染。发热持续时间为12天(1 - 30天),大环内酯类抗生素治疗开始后的发热持续时间为8天(1 - 22天)。
我们的研究表明,具有高抗菌药物耐药水平的大环内酯类耐药(病原体名称未给出)(MRMP)可能是2023年末中国北京该病原体流行的致病因素。迫切需要更多关注MRMP及抗生素选择。